Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate; Brinzolamide; Latanoprost; Ophthalmic Solutions; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Glaucoma or ocular hypertension in both eyes

• Currently being treated with latanoprost 0.005% QD

• IOP greater than or equal to 18mm Hg on latanoprost 0.005%

• Best-corrected VA of 20/200 or better in each eye

• Visual field within 6 months of study entry

Exclusion Criteria:

• Secondary glaucoma

• Active intraocular inflammation or macular edema

• Intraocular surgery or laser surgery within the past 3 months